Adverse Event reporting information can be found in footer

Request a Meeting

PI
Firmagon degarelix. Think beyond the prostate Icon Icon Icon Icon

How can FIRMAGON® help with disease-related symptoms?

What are the relative risk reductions of these symptoms when treating with FIRMAGON® vs LHRH agonists?
Learn More...

These common symptoms can have a negative effect on patients’ quality of life,2,3 potentially impacting the NHS burden:

Urinary-tract problems

Urinary-associated problems, e.g. obstructive uropathy leading to persistent infections and LUTS

Icon of a person with areas of focus on the body highlighting key parts

Bone and back pain

As a result of arthralgia, or eventually bone metastases which can lead to fractures and spinal cord compression

Icon of a person with areas of focus on the body highlighting key parts

FIRMAGON® is significantly more effective in controlling disease-related symptoms vs. LHRH agonists1

A pooled analysis of 5 randomised controlled trials (n=1920) demonstrated that FIRMAGON® significantly reduces joint, musculoskeletal and lower urinary tract symptoms (LUTS) vs. LHRH agonists1

† Absolute values for joint-related signs and symptoms are not reported in the paper.
‡ Crude incidence of a urinary tract event was 12% vs. 18% for FIRMAGON® and LHRH agonist respectively.
§ Crude incidence of a musculoskeletal event was 8% vs. 12% for FIRMAGON® and LHRH agonist respectively

How can FIRMAGON®’s MOA help improve control of disease-related symptoms?

Compared with LHRH agonists, FIRMAGON® blocks GnRH receptors leading to a rapid, profound and sustained suppression of testosterone, FSH, LH and PSA5

Use the buttons below to choose

Musculoskeletal
UT-related event

A pooled analysis of 5 randomised controlled trials by Klotz et al. 2014 revealed the probability of experiencing a musculoskeletal event1

graph

A pooled analysis of 5 randomised controlled trials by Klotz et al. 2014 revealed the probability of experiencing renal or LUTS adverse event1

graph

What impact could the significant reduction of joint, musculoskeletal and LUTS vs. LHRH agonists1 have on your patients with advanced prostate cancer?

?

References

References
1. Klotz L, et al. Eur Urol 2014;66:1101–1108.
2. NHS. Prostate cancer. Symptoms. Available at: https://www.nhs.uk/conditions/prostate-cancer/symptoms/. Last accessed: February 2024.
3. Prostate Cancer UK. Living with prostate cancer. Available at: https://prostatecanceruk.org/prostate-information/living-with-prostate-cancer. Last accessed: February 2024.
4. Drudge-Coates L. Int J Urol Nurs 2009;3(3):85–92.
5. Klotz L, et al. BJU Int 2008;102:1531-1538.

Job Code: UK-FN-2400005 - Date of Preparation: March 2024

cookiepopup

Our use of cookies

We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.

Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.